Related Experiment Video
Updated: Jul 4, 2025
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
miR-338-3p acts as a tumor suppressor in lung squamous cell carcinoma by targeting FGFR2/FRS2
Xia Shan1, Cheng Zhang2, Chunyu Li3
1Department of Respiration, Jiangsu Province Hospital, And Nanjing Medical University First Affiliated Hospital, Nanjing, Jiangsu 210000, China.
Background:
Lung cancer refers to the occurrence of malignant tumors in the lung, and squamous cell carcinoma is one of the most common pathological types of non-small cell lung cancer. Studies have shown that microRNAs (miRNAs) play an important role in the occurrence, development, early diagnosis, and treatment of lung cancer. This study aimed to explore the role and possible mechanism of MicroRNA-338-3p (miR-338-3p) in lung squamous cell carcinoma (LUSC).
Method:
In this study, we compared 238 LUSC patients with relatively high miR-338-3p expression levels with 238 miR-338-3p expression levels in The Cancer Genome Atlas (TCGA)-LUSC dataset using first-line gene set enrichment analysis (GSEA). Second, the mRNA expression of miR-338-3p, FGFR2, and fibroblast growth factor receptor substrate 2 (FRS2) in 30 lung cancers and adjacent lung tissues was detected using quantitative real-time polymerase chain reaction (qRT-PCR). Finally, in vitro experiments were conducted, whereby the expression levels of miR-338-3p in lung cancer cells (H1703, SKMES1, H2170, H520) and normal lung epithelial cells (16HBE) were detected using qRT-PCR. miR-338-3p was overexpressed in lung cancer cells (H1703), and the cell proliferation (cell counting kit-8 [CCK8] assay), colony formation, cell apoptosis, cell cycle (BD-FACSVerse assay, Becton Dickinson, Bedford, MA, USA), cell invasion, and migration (Transwell assay, Thermo Fischer Corporation, Waltham, MA, USA) were detected.
Results:
We found that the expression of miR-338-3p was significantly reduced in LUSC tissues (p < 0.001) and cancer cell lines (P < 0.01), and miR-338-3p was significantly negatively correlated with the expression of FGFR2 (P < 0.001) and FRS2 (P < 0.01). Furthermore, overexpression of miR-338-3p inhibited proliferation (P < 0.001), migration, and invasion (P < 0.001) of LUSC cell lines and increased apoptosis in the G1 phase (P < 0.001) and cell cycle arrest (P < 0.05).
Conclusions:
Our study demonstrates that miR-338-3p inhibits tumor cell proliferation and migration by targeting FGFR2 and FRS2 in LUSC. We believe that miR-338-3p may be a promising target for the treatment of LUSC.
Insights
MicroRNA-338-3p (miR-338-3p) is reduced in lung squamous cell carcinoma (LUSC). Overexpressing miR-338-3p inhibits LUSC cell proliferation and migration by targeting FGFR2 and FRS2, suggesting its therapeutic potential.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Lung squamous cell carcinoma (LUSC) is a major subtype of non-small cell lung cancer.
- MicroRNAs (miRNAs) are crucial regulators in lung cancer development and progression.
- The specific role of microRNA-338-3p (miR-338-3p) in LUSC remains to be fully elucidated.
Purpose of the Study:
- To investigate the expression and function of miR-338-3p in LUSC.
- To explore the potential molecular mechanism of miR-338-3p in LUSC.
- To assess the therapeutic potential of miR-338-3p in LUSC.
Main Methods:
- Gene set enrichment analysis (GSEA) on TCGA-LUSC dataset.
- Quantitative real-time polymerase chain reaction (qRT-PCR) to detect miR-338-3p, FGFR2, and FRS2 expression in tissues and cell lines.
- In vitro assays including CCK-8, colony formation, apoptosis, cell cycle, and Transwell assays to evaluate cell behavior.
Main Results:
- miR-338-3p expression was significantly downregulated in LUSC tissues and cell lines.
- miR-338-3p expression showed a significant negative correlation with FGFR2 and FRS2.
- Overexpression of miR-338-3p suppressed LUSC cell proliferation, migration, and invasion, while inducing apoptosis and cell cycle arrest.
Conclusions:
- miR-338-3p acts as a tumor suppressor in LUSC.
- miR-338-3p inhibits LUSC progression by targeting FGFR2 and FRS2.
- miR-338-3p represents a potential therapeutic target for LUSC treatment.
Related Concept Videos
01:22MicroRNAs
02:38Mitogens and the Cell Cycle
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
02:23Abnormal Proliferation
01:12Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...